Healthcare of Ontario Pension Plan Trust Fund Takes Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 467,800 shares of the company’s stock, valued at approximately $32,535,000. Healthcare of Ontario Pension Plan Trust Fund owned about 0.77% of Structure Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in GPCR. State of Wyoming acquired a new stake in shares of Structure Therapeutics during the 2nd quarter valued at about $28,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares during the last quarter. CWM LLC lifted its holdings in shares of Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 125 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its holdings in shares of Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after buying an additional 1,146 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Structure Therapeutics during the 4th quarter valued at about $127,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

GPCR opened at $43.07 on Tuesday. The business has a 50 day moving average price of $43.44 and a 200 day moving average price of $57.39. The firm has a market cap of $3.06 billion, a P/E ratio of -49.51 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. HC Wainwright reduced their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, June 11th. Citizens Jmp reduced their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, BMO Capital Markets set a $145.00 target price on Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Structure Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $106.75.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.